Health technology — US PTAB Patent Cases
4 decisions indexed
Page 1 of 1 · 4 total
Zepp Health Corporation v.Slyde Analytics, LLC
Zepp Health and Slyde Analytics have settled their dispute over U.S. Patent 9,804,678 and jointly moved to terminate the pending inter partes review. The Board has not yet instituted the proceeding, and the parties cite public‑policy reasons for termination.
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
The PTAB denied an IPR petition filed by Samsung against Oura Health because the patent owner had disclaimed all challenged claims. This denial was based on procedural rules regarding pre-institution claim disclaimer.
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
The PTAB denied Samsung's Post-Grant Review petition against Ouraing because the patent owner had statutorily disclaimed all 16 challenged claims.
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
The PTAB denied institution of an IPR filed by Samsung against Oura Health because the patent owner had formally disclaimed all 12 challenged claims.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.